# GA-68 DOTA-TOC of Somatostatin Positive Malignancies

> **NCT02177773** · PHASE1,PHASE2 · TERMINATED · sponsor: **University of California, San Francisco** · enrollment: 300 (actual)

## Conditions studied

- Neuroendocrine Tumor
- Paraganglioma
- Carcinoid Tumors
- Neuroblastoma

## Interventions

- **PROCEDURE:** Computed Tomography (CT)
- **DRUG:** Gallium Ga 68-Edotreotide
- **PROCEDURE:** Magnetic Resonance Imaging (MRI)
- **PROCEDURE:** Positron Emission Tomography (PET)

## Key facts

- **NCT ID:** NCT02177773
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-06-23
- **Primary completion:** 2017-08-07
- **Final completion:** 2017-08-07
- **Target enrollment:** 300 (ACTUAL)
- **Why stopped:** FDA approved agent for this indication during enrollment
- **Last updated:** 2019-11-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02177773

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02177773, "GA-68 DOTA-TOC of Somatostatin Positive Malignancies". Retrieved via AI Analytics 2026-08-24 from https://api.ai-analytics.org/clinical/NCT02177773. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*